Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes

Endocrine Journal

Volumn 53, Issue 4, 2006, Pages 493-501

  Igarashi, Masahiko ^a   Hirata, Akihiko ^a   Kadomoto, Yuko ^a   Tominaga, Makoto ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Diabetes mellitus; Hypersensitive CRP; Losartan; Proteinuria

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; LABORATORY TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

AGED; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; C-REACTIVE PROTEIN; CYSTATIN C; CYSTATINS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROTEINURIA; TRANSFORMING GROWTH FACTOR BETA;

EID: 33748453675     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-025     Document Type: Article

References (41)

1. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310: 356-360.
2. Remuzzi G, Schieppati A, Ruggenenti P (1997) Nephropathy in patients with type 2 diabetes. N Engl J Med 346: 1145-1151.
3. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH (1997) Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study. BMJ 314: 738-788.
4. Yamaguchi H, Igarashi M, Hirata A, Tsuchiya H, Sugiyama K, Morita Y, Jimbu Y, Ohnuma H, Daimon M, Tominaga M, Kato T (2004) Progression of diabetic nephropathy enhances the serum osteopontin level in type 2 diabetic patients. Endocr J 51: 499-504.
5. Parving HH, Andersen AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1: 1175-1179.
6. Zanchetti A, Hansson L, Dahløf B, Elmfeldt D, Kjeldsen S, Kolloch R, Larochelle P, McInnes GT, Mallion JM, Ruilope L, Wedel H, on behalf of the HOT Study Group (2001) Effect of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. J Hypertens 19: 1149-1159.
7. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR (2003) Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225-232.
8. Igarashi M, Jimbu Y, Hirata A, Tominaga M (2005) Characterization of plasma brain natriuretic peptide level in patients with type 2 diabetes. Endocr J 52: 353-362.
9. Dzau VJ (1994) Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens 12 (Suppl): S3-S10.
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462.
11. Ravid M, Lang R, Rachmani R, Lishner M (1996) Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus: A 7-year follow-up study. Arch Intern Med 156: 286-289.
12. Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA (2004) Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 27: 1330-1334.
13. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators (2001) Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869.
14. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Raz I, Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860.
15. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, for the Diabetes Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961.
16. McMurray JJV (2001) Heart failure: Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart 86: 97-103.
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20: 1183-1197.
18. Kamata K, Tochikubo O (2002) Estimation of 24-h urinary sodium excretion using lean body mass and overnight urine collected by a pipe-sampling method. J Hypertens 20: 2191-2197.
19. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000) Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321: 1440-1444.
20. Rossing K, Christensen PK, Jensen BR, Parving HH (2002) Dual blockade of the renin-angiotensin system in diabetic nephropathy: A randomized double-blind cross-over study. Diabetes Care 25: 95-100.
21. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH (2002) Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17: 1019-1024.
22. Plum J, Bünten B, Nemeth R, Grabensee B (1998) Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 9: 2223-2234.
23. Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME, Allen TJ (2003) Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: Potential role of nephrin. J Hypertens 21: 209-216.
24. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippen J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ (2004) Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 65: 30-39.
25. Epstein M (2001) Aldosterone as a mediator of progressive renal disease: Pathogenic and clinical implications. Am J Kidney Dis 37: 677-688.
26. Hostetter TH, Rosenberg ME, Ibrahim HN, Juknevicius I (2001) Aldosterone in progressive renal disease. Semin Nephrol 21: 573-579.
27. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, Bonizzato A, Graziani M, Anker SD, Coats AJS, Zardini P (2001) Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 37: 1808-1812.
28. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH (2004) Aldosterone escape during angiotensin II receptor blockade in diabetic nephropathy is associated with enhanced decline in GFR. Diabetologia 47: 1936-1939.
29. Christlieb AR, Kaldany A, D'Elia JA (1976) Plasma renin activity and hypertension in diabetes mellitus. Diabetes 25: 969-974.
30. Tuck ML, Sambni MP, Levin L (1979) Hyporeninemic hypoaldosteronism in diabetes mellitus: Studies of the autonomic nervous system's control of renin release. Diabetes 28: 237-241.
31. 1 in membranous glomerulonephritis. Nephrol Dial Transplant 12: 2562-2568.
32. 1 plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 12: 822-827.
33. Agarwal R, Siva S, Dunn SR, Sharma K (2002) Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels. Am J Kidney Dis 39: 486-492.
34. Christensson AG, Grubb AO, Nilsson JA, Norrgren K, Sterner G, Sundkvist G (2004) Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. J Intern Med 256: 510-518.
35. Perkins BA, Nelson RG, Ostrabder BE, Blouch KL, Krolewski AS, Myers BD, Warram JH (2005) Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration; results of a 4-year follow-up study. J Am Soc Nephrol 16: 1402-1412.
36. Ridker PM, Rifal N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565.
37. 1 receptor-independent functions of losartan. Circ Res 90: 754-756.
38. Liu EC, Hedberg A, Goldenberg HJ, Harris DN, Webb ML (1992) DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. Prostaglandins 44: 89-99.
39. Usui M, Egashira K, Tomita H, Koyanagi M, Katoh M, Shimokawa H, Takeya M, Yoshimura T, Matsushima K, Takeshita A (2000) Important role of local angiotensin II activity mediated via a type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 101: 305-310.
40. Krämer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, Böger RH, Forssmann WG, Drexler H, Schieffer B (2002) Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan. Role of the active metabolite EXP3179. Circ Res 90: 770-776.
41. Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T, Kintscher U (2006) Regulation of peroxisome proliferator-activated receptor γ activity by losartan metabolites. Hypertension 47: 586-589.